Cargando…

Fronteras en la esclerosis múltiple /

Detalles Bibliográficos
Otros Autores:	Cuevas García, Carlos F.
Formato:	Libro
Lenguaje:	Spanish
Publicado:	Mexico, DF : Planeación y Desarrollo Editorial, c2007.
Materias:	Esclerosis múltiple

Ejemplares similares

Esclerosis múltiple /
por: Fernández, Óscar
Publicado: (2003)

Esclerosis múltiple
por: Fernández Férnandez, Oscar

Esclerosis múltiple /
Publicado: (2011)

Multiple sclerosis /
por: Warren, Sharon
Publicado: (2001)

Die multiple Sklerose ; ihre lymphogene Entstehung und ihre polyvalente Behandlung.
por: Selzer, Hans
Publicado: (1970)

El manejo integral de los pacientes con esclerosis múltiple /
Publicado: (2003)

Esclerosis sistémica
por: Vera Lastra, Olga Lidia
Publicado: (2010)

La calidad de vida en la esclerosis múltiple desde una perspectiva interdisciplinar
por: Rivera Navarro, Jesús
Publicado: (2003)

Rehabilitación en la esclerosis múltiple /
por: Paez Sartorius, María Eugenia
Publicado: (1987)

Tratamiento de la esclerosis múltiple : revisión bibliográfica /
por: Flores Feria, José Alberto
Publicado: (1992)

Síndrome de Nicolau por fármacos autoinyectables en la esclerosis múltiple
por: Neri, M. José, et al.
Publicado: (2023)

Esclerosis múltiple progresiva" : con presentación de caso clínico observado en el hospital Dr. Luis F. Nachón/
por: Pérez Ramírez, Angela
Publicado: (1994)

The contribution of neuropathology to multiple sclerosis research
por: Lassmann, Hans
Publicado: (2022)

Imaging outcomes for trials of remyelination in multiple sclerosis
por: Mallik, Shahrukh, et al.
Publicado: (2014)

Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis
por: Manjaly, Zina-Mary, et al.
Publicado: (2019)

Decision making and framing effects in multiple sclerosis
por: Zamarian, Laura, et al.
Publicado: (2020)

La variabilidad genética en la asociación esclerosis múltiple y el virus Epstein-Barr
por: Rivera-Silva, Gerardo
Publicado: (2022)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Stressful life events are associated with the risk of multiple sclerosis
por: Jiang, X., et al.
Publicado: (2020)

Association of adverse childhood experiences with the development of multiple sclerosis
por: Eid, Karine, et al.
Publicado: (2022)

Impact of CYBA genotypes on severity and progression of multiple sclerosis
por: Törnell, Andreas, et al.
Publicado: (2022)

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
por: Cerqueira, João J, et al.
Publicado: (2018)

The grey matter correlates of impaired decision-making in multiple sclerosis
por: Muhlert, Nils, et al.
Publicado: (2015)

MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
por: Resende Salgado, Lucas, et al.
Publicado: (2018)

Structural network disruption markers explain disability in multiple sclerosis
por: Charalambous, Thalis, et al.
Publicado: (2019)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

Diagnosis and treatment of progressive multiple sclerosis: A position paper
por: Pozzilli, Carlo, et al.
Publicado: (2022)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Tobacco smoking and excess mortality in multiple sclerosis: a cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2014)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics
por: Nij Bijvank, Jenny, et al.
Publicado: (2022)

Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Brain age as a surrogate marker for cognitive performance in multiple sclerosis
por: Denissen, Stijn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_73lpe0e3sdjum63qge0168bv2d